Pemdrax 100 Injection contains Pemetrexed 100mg, a broad-spectrum antineoplastic agent indicated for the treatment of non-small cell lung cancer and malignant pleural mesothelioma. It helps in inhibiting tumor growth and slowing disease progression as part of modern chemotherapy regimens.
Pemetrexed works by disrupting folate-dependent metabolic processes essential for DNA and RNA synthesis in cancer cells, thereby preventing cell replication and promoting apoptosis. Its injectable formulation allows precise dosing under controlled oncology care settings.
For distributors and healthcare suppliers, Pemdrax 100 Injection is a high-value oncology therapy product, widely used in cancer hospitals, specialty oncology centers, and tertiary care institutions. The rising incidence of lung cancer ensures sustained demand in the oncology segment.
Adding Pemdrax 100 Injection to your oncology and anticancer therapy segment creates strong opportunities in hospital supply chains, specialty cancer centers, export markets, and third-party manufacturing. Its established clinical role, strong prescriber confidence, and critical therapeutic importance make it a valuable addition to pharmaceutical distribution portfolios.